Get the Stockscreener App
105.26
0.73%
0.76
After Hours:
105.24
-0.02
-0.02%
Boston Scientific Corp stock is traded at $105.26, with a volume of 10.58M.
It is up +0.73% in the last 24 hours and up +2.45% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$104.50
Open:
$104.52
24h Volume:
10.58M
Relative Volume:
1.29
Market Cap:
$155.73B
Revenue:
$17.55B
Net Income/Loss:
$2.03B
P/E Ratio:
76.83
EPS:
1.37
Net Cash Flow:
$2.72B
1W Performance:
+0.73%
1M Performance:
+2.45%
6M Performance:
+16.10%
1Y Performance:
+40.35%
1-Day Range:
$104.08
$105.36
1-Week Range:
$103.50
$106.67
52-Week Range:
$71.88
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific’s longtime DEI, HR leader exits for chief HR role at new company - MassDevice
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scientific Corp (BSX) - GuruFocus
Piper Sandler maintains Boston Scientific stock at Overweight - Investing.com
Continence Care Market Size to Surpass USD 9.54 Billion by 2031 With 5.6% CAGR, Surging Prevalence of Chronic Diseases Propels the Demand | The Insight Partners - GlobeNewswire Inc.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook - Benzinga
Boston Scientific (BSX) Ends Acurate TAVR Program, Shifts Focus to Promising Projects | BSX Stock News - GuruFocus
BSX: Analyst Reiterates Buy Rating for Boston Scientific | BSX S - GuruFocus
In TAVR setback, Boston Sci pulls plug on Acurate valves - BioWorld MedTech
Boston Scientific discontinues Acurate TAVR sales, cites regulatory burden - MassDevice
Boston Scientific Ends ACURATE Valve Sales By Investing.com - Investing.com Canada
Evercore ISI maintains Boston Scientific stock at Outperform - Investing.com
TD Cowen maintains Boston Scientific stock at $115 target By Investing.com - Investing.com South Africa
TD Cowen maintains Boston Scientific stock at $115 target - Investing.com
Boston Scientific (BSX) Discontinues Sales of ACURATE Aortic Valve Systems - GuruFocus
Boston Scientific (BSX) Discontinues Valve Product Amid Regulato - GuruFocus
JPMorgan maintains Boston Scientific stock with $135 target - Investing.com
Boston Scientific ends TAVR sales; J&J shares Monarch robot data - Yahoo Finance
Citi maintains Buy on Boston Scientific, keeps $125 target - Investing.com
Needham sees Boston Scientific stock as a buy, target at $115 - Investing.com
Boston Scientific (BSX) Halts Aortic Valve Systems, Boosting Com - GuruFocus
Boston Scientific (BSX) Halts Global Sales of ACURATE Valve Syst - GuruFocus
Boston Scientific at Bernstein Conference: Strategic Growth and Innovation - Investing.com
Abercrombie & Fitch, Boston Scientific, DoorDash - TradingView
Boston Scientific (BSX) Halts Global Sales of ACURATE Valve Systems | BSX Stock News - GuruFocus
Boston Scientific Ends ACURATE Valve Sales - Investing.com
Boston Scientific shares drop as valve systems are discontinued - Investing.com
Boston Scientific plans changes to expected $200M tariff hit as situation shifts - Yahoo Finance
Boston Scientific (NYSE:BSX) Q1 Earnings: Leading The Medical Devices & SuppliesDiversified Pack - Yahoo Finance
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Citigroup | BSX S - GuruFocus
India Catheters Market Set to Witness Significant Growth - openPR.com
Was Jim Cramer Right About Boston Scientific Corporation (BSX)? - Insider Monkey
Endoscopy Devices Global Market Overview 2021-2030 with Forecasts 2024-2030 - GlobeNewswire Inc.
Boston Scientific Acurate neo2 fails to meet non-inferiority in study - MassDevice
July 3rd Options Now Available For Boston Scientific (BSX) - Nasdaq
Investors in Boston Scientific (NYSE:BSX) have seen splendid returns of 182% over the past five years - Yahoo Finance
Boston Scientific (BSX) Target Price Increased by Citi Analyst | - GuruFocus
Boston Scientific (BSX) Target Price Increased by Citi Analyst | BSX Stock News - GuruFocus
Boston Scientific has positive real-world Acurate Prime TAVI data - MassDevice
Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago - Yahoo Finance
$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much TodayBoston Scientific (NYSE:BSX) - Benzinga
Boston Scientific’s rating upgraded to A3 by Moody’s Ratings - Investing.com
Market shift: Boston Scientific emerges as Massachusetts' most valuable public company - The Business Journals
Boston Sci Closes Division Sale to Stryker Corp. On Jan. 3, Boston Scientific Corp. completed the - Medical Product Outsourcing
Boston Scientific Adds Seat to Board - Medical Product Outsourcing
Boston Scientific and Other Firms Gain Favorable Ruling in Patent Infringement Case - Medical Product Outsourcing
Boston Scientific Loses Federal Case Over Vaginal Mesh Product - Medical Product Outsourcing
Boston Scientific (NYSE:BSX) Ticks All The Boxes When It Comes To Earnings Growth - Yahoo Finance
Boston Scientific Expands Board with Two New Members - Medical Product Outsourcing
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):